Humalog market forecast points to steady growth through 2030
The Business Research Company says the global Humalog (insulin lispro) market is set to rise from $9.27 million in 2025 to $14.28 million by 2030 as diabetes cases climb and insulin use expands. North America held the largest share in 2025, while the report adds new forecasting tools and regional analysis.
Why it matters: - Rising diabetes rates are increasing demand for fast-acting insulin therapies such as Humalog. - The report's forecast points to steady market expansion through 2030, which matters for insulin access, distribution and treatment planning.
What happened: - The Business Research Company released its Humalog (insulin lispro) market report covering market size, trends and a global forecast for 2026-2035. - The report says the global Humalog market was worth $9.27 million in 2025. - The market is projected to reach $10.13 million in 2026. - The report projects the market will rise to $14.28 million by 2030. - North America held the largest share of the global Humalog market in 2025.
The details: - The report ties growth to more insulin-dependent patients, wider use of recombinant insulin therapies and broader clinical acceptance of insulin lispro. - Humalog's rapid action helps control post-meal glucose spikes, making it a key option in diabetes management. - The report cites rising obesity, sedentary lifestyles, unhealthy diets, aging populations, urbanization, genetic factors and better diagnosis as drivers of diabetes prevalence. - The Institute for Health Metrics and Evaluation said in June 2023 that more than 500 million people globally were living with diabetes and that the total could climb to 1.3 billion by 2050. - The report also links market growth to higher healthcare spending, which can improve access to insulin therapies and lower patient costs. - The UK Office for National Statistics reported a 5.6% increase in healthcare spending from 2022 to 2023, reaching about $317.63 billion (£292 billion) in 2023. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The company posted sample and full-report links: Download a free sample of the report and View the full report.
Between the lines: - The forecast suggests Humalog demand is being pulled more by chronic disease trends than by short-term market swings. - The focus on forecasting dashboards and TAM analysis signals that the report is aimed at companies assessing growth opportunities, not just clinicians or investors.
What's next: - The report expects continued growth as diabetes prevalence rises and healthcare spending expands. - Regional performance will likely stay uneven, with North America already leading and other markets depending on access, diagnosis rates and reimbursement trends. - The Business Research Company is directing readers to its sales contacts and social channels for follow-up information.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Analysis
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.